Company Overview and News

 
BRIEF-PTC Entered Accelerated Repurchase Agreement To Repurchase $100 Mln Common Stock

2018-04-20 reuters
* PTC - ENTERED ACCELERATED REPURCHASE AGREEMENT TO REPURCHASE $100 MILLION COMMON STOCK, WITH INITIAL DELIVERY OF 80% OF SHARES TO BE REPURCHASED
Upvote Downvote

 
PTC / PTC Inc. FORM 8-K (Current Report)

2018-04-20 sec.gov
Blueprint UNITED STATES
Upvote Downvote

 
PTC / PTC Inc. FORM 8-K (Current Report)

2018-04-18 sec.gov
Blueprint UNITED STATES
Upvote Downvote

 
Buy Ecolab If It Goes Down - Cramer's Lightning Round (4/17/18)

2018-04-18 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, April 17.
Upvote Downvote

 
Cramer's lightning round: Don't buy Dr. Pepper until after its merger

2018-04-17 cnbc
Dr. Pepper Snapple Group: "It is so hard to understand this merger because they're going to give you a dividend. No one wants a dividend. You're going to have to wait until this deal now closes. That's my best bet. And then I'm going to be probably pushing it pretty hard, but the deal's got to close, the dividend's got to go and then it'll be OK."
Upvote Downvote

 
Is a Surprise Coming for PTC Inc. (PTC) This Earnings Season?

2018-04-17 zacks
Investors are always looking for stocks that are poised to beat at earnings season and PTC Inc. (PTC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Upvote Downvote

2
Zacks Industry Outlook Highlights: AES, NextEra Energy, JinkoSolar Holding and First Solar

2018-04-16 zacks
Chicago, IL – April 16, 2018 – Today, Zacks Equity Research discusses the Industry: Alternative Energy, Part 2, including AES Corp. (AES - Free Report) , NextEra Energy (NEE - Free Report) , JinkoSolar Holding (JKS - Free Report) and First Solar (FSLR - Free Report) .
Upvote Downvote

 
Alternative Energy Sees Cost Cuts, Corporate Ventures

2018-04-13 zacks
The broad consensus on the man-made nature of climate change notwithstanding, policies of the current U.S. administration run counter to it and favorable to the coal industry. But not all is lost – as a big part of the corporate sector and many local governments remain committed to taking steps to ensure a cleaner energy environment.
Upvote Downvote

 
PTC / PTC Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-04-10 sec.gov
SCHEDULE 13G Amendment No. 1 PTC INC COMMON STOCK Cusip #69370C100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #69370C100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,121,102 Item 6: 0 Item 7: 13,852,752 Item 8: 0 Item 9: 13,852,752 Item 11: 11.912% Item 12: HC Cusip #69370C100 Item 1: Reporting Person - Abigail P.
Upvote Downvote

 
PTC / PTC Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-04-10 sec.gov
SCHEDULE 13G Amendment No. 1 PTC INC COMMON STOCK Cusip #69370C100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #69370C100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,121,102 Item 6: 0 Item 7: 13,852,752 Item 8: 0 Item 9: 13,852,752 Item 11: 11.912% Item 12: HC Cusip #69370C100 Item 1: Reporting Person - Abigail P.
Upvote Downvote

 
Zacks.com highlights: Live Nation Entertainment, PTC, AMC Entertainment Holdings, Mattel and Covanta Holding

2018-04-06 zacks
Chicago, IL – April 6, 2018 - Stocks in this week’s article include: Live Nation Entertainment, Inc. (LYV - Free Report) , PTC Inc. (PTC - Free Report) , AMC Entertainment Holdings, Inc. (AMC - Free Report) , Mattel, Inc. (MAT - Free Report) and Covanta Holding Corporation (CVA - Free Report) .
Upvote Downvote

 
Infrastructure And Energy Alternatives: Wind At Their Back With 25% FCF Yield

2018-04-06 seekingalpha
IEA is an undiscovered, newly public renewables focused E&C company with a compelling valuation – 3.8x 2018 EV/EBITDA and a free cash flow yield of around 25% and record backlog.
Upvote Downvote

 
5 Toxic Stocks to Abandon or Sell Short for Profits

2018-04-05 zacks
Investing success depends upon proper identification of overhyped toxic stocks and the correctly priced ones. However, spotting toxic stocks on time and discarding them to make profit is not an easy task. Overpriced toxic stocks are generally susceptible to external shocks. Additionally, these stocks are loaded with huge debts. The price of the toxic stocks is artificially inflated. However, the higher price of toxic stocks is only short-term in nature as it exceeds its true intrinsic value.
Upvote Downvote

 
Autodesk: A Bumpy Road Ahead

2018-04-05 seekingalpha
The company has started transition to subscription model several years ago, but it has to prove its effectiveness.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 69370C100